DAXX and diffuse large B-cell lymphoma: Moreover, in diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma, high levels of eIF4B increase the expression of key survival proteins, including BCL-2, DAXX and ERCC5, and are prognostic of poor patient outcome (11).